期刊文献+

糖尿病大鼠周围神经bFGF的动态表达及巴曲酶对其的影响

The impact of Batroxobin on the dynamic expression of bFGF in peripheral nerve of diabetic rats
下载PDF
导出
摘要 目的探讨碱性成纤维生长因子(bFGF)在糖尿病周围神经病(DPN)大鼠中的动态变化规律;观察巴曲酶对bFGF的影响及其机制,为临床上治疗DPN提供理论依据。方法将大鼠腹腔注射链脲佐菌素制作实验性糖尿病模型,分别于成模后2m和3m时腹腔注射巴曲酶进行干预。通过免疫组织化学和原位杂交双重检测bF-GF在坐骨神经中的表达。结果DM造模后2m时坐骨神经中bFGF的含量明显减少,且随时间变化有统计学差异,巴曲酶治疗后bFGF的表达明显增加。结论DPN大鼠坐骨神经中bFGF表达减少可能参与DPN的发病机制。巴曲酶对DPN有保护作用,其机制可能包括对bFGF的调节。 Objective To investigate the dynamic expression of bFGF in diabetic peripheral neuropathy(DPN)rats and to confirm the impact of Batroxobin on bFGF tentatively and the mechanisms,in order to furnish the theory foundation for the therapy of DPN clinically. Methods Animal models for experimental diabetes were prepared through the peritoneal injection of streptozocin. Batroxobin were injected intraperitoneal respectively in 2 months and 3 months after the formation of DM model for intervention. Through the immunohistochemistry and hybridization in situ,the expression of bFGF in ischiadic nerve of the rats was detected. Results The content of bFGF in ischiadic nerve decreased obviously 2 months after the formation of DM model and it had time-varying statistics diversity. However,the expression of bFGF was markedly increased after the treatment of Batroxobin. Conclusion The decreased expression of bFGF in ischiadic nerve in DPN rats might play an important role in the pathogenesis of DPN. Treatment with Batroxobin is beneficial in the prevention of DPN,possibly through the regulation of the expression level of bFGF in the sciatic nerves of the DPN rats.
出处 《中风与神经疾病杂志》 CAS CSCD 北大核心 2010年第3期226-229,共4页 Journal of Apoplexy and Nervous Diseases
  • 相关文献

参考文献7

二级参考文献29

  • 1刘嵋,张金辉.糖尿病性神经病变的药物治疗现状[J].中华内分泌代谢杂志,1996,12(1):37-39. 被引量:193
  • 2张玉华,万琪.巴曲酶对血小板功能影响的观察[J].中风与神经疾病杂志,1996,13(5):267-268. 被引量:16
  • 3Bovill EG,Becker R,Tracy RP. Monitoring thrombolytic therapy[J]. Prog Cardiovase Dis, 1992,34(4): 235.
  • 4强丽娟 林菊香 吴松寒.东菱克栓酶治疗脑梗塞的临床观察[J].中风与神经疾病杂志,1995,12(2):111-111.
  • 5Piechota G,Malkiewicz J,Karwat ZD. Diabetes mellitus type 2 as a cause of disability[J]. Przegl Epidemiol,2004,58(4):677-82.
  • 6Gabbay KH. Aldose reductase inhibition in the treatment of diabetic neuropathy:where are we in 2004[J]? Curr Diab Rep,2004,4(6) :405-8.
  • 7Price SA, Agthong S, Middlemas AB, et al. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy:interactions with aldose reductase[J]. Diabetes, 2004,53(7) : 1851-6.
  • 8Coste TC,Gerbi A,Vague P,et al. Peripheral diabetic neuropathy and polyunsaturated fatty acid supplementations:natural sources or biotechnological needs[J]? Cell Mol Biol (Noisy-le-grand),2004,50 (7) :845-53.
  • 9Giannini C,Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity[J]. Ann Neurol,1995,37(4) :498-504.
  • 10Ziegler D, Sohr CG, Neurooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy[J]. Diabetes Care,2004,27(9) :2178-83.

共引文献456

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部